drugset / Trial / NCT03579836
Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is a single center, open-label, non-comparative, phase I/II clinical trial to assess the maximum tolerated dose (MTD), safety and efficacy of BEY1107 in monotherapy and in combination with gemcitabine in patient With locally advanced or metastatic pancreatic cancer.
Timeline
- Start
- 2018-05-14
- Primary completion
- 2026-11-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AVOTACICLIB | Small molecule | — | Oral |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
Indications
No indication recorded.